In an interview to CNBC-TV18, Surajit Pal of Prabhudas Lilladher said he was not very bullish about the US business of Lupin . The company on Wednesday had received preliminary approval from the US FDA to market a generic equivalent of GlaxoSmithKline Plc’s ViiV Healthcare’s (ViiV) antiretroviral (ARV) Lexiva tablets in 700 milligram dosage form. This product was filed from the company's Goa plant which has run into a problem with the US FDA. The approval for the anti-retroviral drug is being interpreted by a section of the market as a clean chit for the Goa plant. However, Pal said Lupin could not confirm whether to read this as Establishment Inspection Report (EIR) or not. Pal feels that unless and until the company receives an EIR, it cannot confirm that the Goa plant is out of the US FDA's crosshair. Also watch accompanying video of Praful Bohra, VP-Research at Religare Capital Markets with Ekta Batra & Prashant Nair on CNBC-TV18, in which he shared his readings and outlook on Lupin.
0 comments:
Post a Comment